source
- Odyssey, on second try, snags $279M in an IPOAfter withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…BioPharma Dive · 3mo ago↗ source
- Fraudulent citations, blamed on AI hallucinations, are becoming more common in research papers“Fabricated” citations that do not reference real academic papers are spreading in the literature, polluting the public record of science, a new study foundSTAT · 3mo ago↗ source
- Sarepta tumbles as its gene therapy sales decline furtherEven though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.BioPharma Dive